↓ Skip to main content

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy

Overview of attention for article published in Gynecologic Oncology Research and Practice, June 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)

Mentioned by

news
8 news outlets
twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy
Published in
Gynecologic Oncology Research and Practice, June 2017
DOI 10.1186/s40661-017-0046-9
Pubmed ID
Authors

Brett A. Miles, Bradley J. Monk, Howard P. Safran

Abstract

Immune responses to the facultative intracellular bacterium Listeria monocytogenes (Lm) are robust and well characterized. Utilized for decades as a model of host-disease immunology, Lm is well suited for use as an immunotherapeutic bacterial vector for the delivery of foreign antigen. Genetic modification of Lm has been undertaken to create an attenuated organism that is deficient in its master transcriptional regulator, protein-related factor A, and incorporates a truncated, nonhemolytic version of the listeriolysin O (LLO) molecule to ensure its adjuvant properties while also preventing escape of the live organism from the phagolysosome. Delivery of a vaccine construct (Lm-LLO-E7; axalimogene filolisbac [AXAL] or ADXS11-001) in which the modified LLO molecule is fused with the E7 oncoprotein of human papillomavirus type 16 (HPV-16) consistently stimulates strong innate and E7 antigen-specific adaptive immune responses, resulting in reduction of tumor burden in animal cancer models. In the clinical setting, AXAL has shown early promise in phase I/II trials of women with cervical cancer, and several more trials are currently underway to assess the efficacy and safety of this antitumor vaccine in patients with HPV-positive head and neck and anal cancers.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 19%
Student > Doctoral Student 4 15%
Student > Master 3 11%
Researcher 2 7%
Student > Bachelor 1 4%
Other 5 19%
Unknown 7 26%
Readers by discipline Count As %
Medicine and Dentistry 8 30%
Biochemistry, Genetics and Molecular Biology 4 15%
Immunology and Microbiology 3 11%
Agricultural and Biological Sciences 2 7%
Unspecified 1 4%
Other 2 7%
Unknown 7 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 65. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2017.
All research outputs
#271,121
of 13,643,788 outputs
Outputs from Gynecologic Oncology Research and Practice
#3
of 28 outputs
Outputs of similar age
#11,100
of 261,427 outputs
Outputs of similar age from Gynecologic Oncology Research and Practice
#1
of 1 outputs
Altmetric has tracked 13,643,788 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 28 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one scored the same or higher as 25 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,427 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them